Pharmacy Daily | New endo treatments?

BAYER HealthCare and Evotec AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Under the agreement both parties will contribute innovative drug targets and technology infrastructures and will share the responsibility for early research and preclinical characterisation of potential clinical candidates in the disease area of endometriosis. “Endometriosis is a disease with insufficient treatment options today for women who suffer from this painful condition,” said Prof. Andreas Busch, Head of Global Drug Discovery. “It is one of Bayer’s strategic research indications and our new collaboration with Evotec will perfectly complement our activities in this field of high unmet medical need. “We look forward to working with Evotec’s team on the development of novel drug candidates,” Busch added.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 02 Oct 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Oct 12